Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19232045 | TYPE V CAS PROTEINS AND APPLICATIONS THEREOF | June 2025 | October 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 19092639 | APTAMER AND RIBOZYME EQUILIBRIUM SHIFTING (ARES) RNA CIRCUITS AND USES THEREOF | March 2025 | March 2026 | Allow | 11 | 1 | 1 | No | No |
| 19085903 | Compositions and Methods for NK-92 Cells Expressing Native CD16 | March 2025 | March 2026 | Allow | 12 | 2 | 1 | No | No |
| 19066066 | EXPRESSION SYSTEM FOR PRODUCT MANUFACTURING | February 2025 | September 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19064383 | NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS | February 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 19028916 | METHODS FOR SEQUENCING SAMPLES | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19028930 | Product, system and method of cell cultivation | January 2025 | December 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18959371 | SUPPLEMENTATION OF LIVER ENZYME EXPRESSION | November 2024 | November 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18941863 | Controllable Transcription | November 2024 | July 2025 | Allow | 8 | 1 | 1 | No | No |
| 18805534 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | August 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18805023 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18799681 | SYSTEM AND PROCESS FOR IN VIVO MANUFACTURING NANOSTRUCTURE-ENDED DOUBLE-STRANDED COVALENTLY-CLOSED LINEAR DNA, THE RESULTING MOLECULES AND THEIR USES | August 2024 | September 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18834523 | Recombinant Humanized Collagen Type I Alpha-1 (rhCol1A1), and Expression Vector and Use Thereof | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18789158 | ENGINEERED GUIDE SCAFFOLDS | July 2024 | October 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18586417 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | February 2024 | August 2024 | Allow | 5 | 1 | 1 | No | No |
| 18425204 | SEQUENCE SPECIFIC ANTIMICROBIALS | January 2024 | January 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18418774 | METHODS FOR SEQUENCING SAMPLES | January 2024 | October 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18418781 | METHODS FOR SEQUENCING SAMPLES | January 2024 | November 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18533538 | METHODS FOR SEQUENCING SAMPLES | December 2023 | October 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18527576 | ELECTROPORATION, DEVELOPMENTALLY-ACTIVATED CELLS, PLURIPOTENT-LIKE CELLS, CELL REPROGRAMMING AND REGENERATIVE MEDICINE | December 2023 | October 2025 | Abandon | 23 | 3 | 1 | No | No |
| 18518914 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | November 2023 | February 2024 | Allow | 3 | 1 | 1 | Yes | No |
| 18488261 | NOVEL CRISPR ENZYMES AND SYSTEMS | October 2023 | November 2024 | Allow | 13 | 2 | 1 | No | No |
| 18451315 | CRISPR ENZYMES AND SYSTEMS | August 2023 | June 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18356900 | METHODS FOR SEQUENCING SAMPLES | July 2023 | March 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18356906 | METHODS FOR SEQUENCING SAMPLES | July 2023 | September 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18355017 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | July 2023 | July 2024 | Allow | 12 | 1 | 1 | No | No |
| 18345958 | FUNCTIONAL GENOMICS USING CRISPR-CAS SYSTEMS FOR SATURATING MUTAGENESIS OF NON-CODING ELEMENTS, COMPOSITIONS, METHODS, LIBRARIES AND APPLICATIONS THEREOF | June 2023 | August 2025 | Allow | 25 | 4 | 1 | Yes | No |
| 18345935 | NOVEL CRISPR ENZYMES AND SYSTEMS | June 2023 | February 2025 | Allow | 19 | 3 | 1 | Yes | No |
| 18208262 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | June 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18204329 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | May 2023 | November 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18316698 | POLYPEPTIDES USEFUL FOR GENE EDITING AND METHODS OF USE | May 2023 | August 2024 | Allow | 15 | 3 | 1 | Yes | No |
| 18189201 | COMPOSITIONS AND METHODS FOR TARGETING, EDITING, OR MODIFYING GENES | March 2023 | December 2024 | Allow | 21 | 3 | 1 | Yes | No |
| 18176197 | METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS | February 2023 | March 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18174013 | CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS USING A VLP-REPLICON | February 2023 | March 2024 | Allow | 13 | 2 | 0 | No | No |
| 18154299 | TRANSCRIPTIONAL CONTROL IN PROKARYOTIC CELLS USING DNA-BINDING REPRESSORS | January 2023 | December 2023 | Allow | 11 | 1 | 1 | No | No |
| 18088274 | METHODS FOR SPATIAL ANALYSIS USING TARGETED RNA DEPLETION | December 2022 | August 2023 | Allow | 7 | 1 | 0 | No | No |
| 18076262 | TUNING CASCADE ASSAY KINETICS VIA MOLECULAR DESIGN | December 2022 | June 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18058251 | GUIDE SCAFFOLDS | November 2022 | May 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18053269 | METHODS AND COMPOSITIONS FOR SIMULTANEOUS EDITING OF BOTH STRANDS OF A TARGET DOUBLE-STRANDED NUCLEOTIDE SEQUENCE | November 2022 | November 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 18050982 | MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES | October 2022 | September 2023 | Allow | 11 | 1 | 0 | No | No |
| 17958973 | COMPOSITIONS AND METHODS FOR TARGETING, EDITING, OR MODIFYING GENES | October 2022 | January 2025 | Allow | 28 | 4 | 1 | Yes | No |
| 17905617 | NOVEL OMNI-59, 61, 67, 76, 79, 80, 81, AND 82 CRISPR NUCLEASES | September 2022 | November 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17820444 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | August 2022 | June 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17817877 | SEQUENTIAL GENE EDITING IN PRIMARY IMMUNE CELLS | August 2022 | April 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17877121 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | July 2022 | April 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17877106 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | July 2022 | April 2023 | Allow | 9 | 3 | 0 | Yes | No |
| 17811391 | CRISPR-BASED PROGRAMMABLE RNA EDITING | July 2022 | September 2024 | Allow | 26 | 3 | 1 | Yes | Yes |
| 17857923 | CLASS II, TYPE II CRISPR SYSTEMS | July 2022 | December 2023 | Allow | 17 | 2 | 1 | No | No |
| 17853753 | CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING | June 2022 | March 2023 | Allow | 8 | 1 | 0 | No | No |
| 17848563 | NOVEL CRISPR ENZYMES AND SYSTEMS | June 2022 | May 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17836222 | RNA ADENO-ASSOCIATED VIRUS (RAAV) VECTOR AND USES THEREOF | June 2022 | February 2024 | Allow | 26 | 2 | 1 | Yes | No |
| 17751999 | END-TO-END CELL THERAPY AUTOMATION | May 2022 | July 2023 | Allow | 14 | 3 | 0 | No | No |
| 17752021 | END-TO-END CELL THERAPY AUTOMATION | May 2022 | May 2023 | Allow | 12 | 2 | 0 | No | No |
| 17774284 | CRISPR AND AAV STRATEGIES FOR X-LINKED JUVENILE RETINOSCHISIS THERAPY | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17735494 | METHODS AND SYSTEMS FOR IDENTIFYING TARGET GENES | May 2022 | March 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17716816 | SAFE HARBOR LOCI | April 2022 | July 2023 | Allow | 15 | 1 | 1 | No | No |
| 17707074 | SEQUENCE SPECIFIC ANTIMICROBIALS | March 2022 | September 2022 | Allow | 6 | 1 | 0 | No | No |
| 17707049 | SEQUENCE SPECIFIC ANTIMICROBIALS | March 2022 | September 2022 | Allow | 6 | 1 | 0 | No | No |
| 17707061 | SEQUENCE SPECIFIC ANTIMICROBIALS | March 2022 | September 2022 | Allow | 6 | 1 | 0 | No | No |
| 17683235 | MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17679203 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST | February 2022 | April 2023 | Allow | 14 | 1 | 0 | No | No |
| 17676210 | CURING FOR RECURSIVE NUCLEIC ACID-GUIDED CELL EDITING | February 2022 | December 2022 | Allow | 10 | 1 | 0 | Yes | No |
| 17584028 | EXPRESSION CONSTRUCTS AND METHODS OF GENETICALLY ENGINEERING METHYLOTROPHIC YEAST | January 2022 | December 2023 | Allow | 23 | 3 | 1 | Yes | No |
| 17581467 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | January 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17581614 | SEQUENCE SPECIFIC ANTIMICROBIALS | January 2022 | August 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17572208 | ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS | January 2022 | February 2024 | Allow | 25 | 3 | 1 | Yes | No |
| 17555395 | INSTRUMENTS, MODULES, AND METHODS FOR IMPROVED DETECTION OF EDITED SEQUENCES IN LIVE CELLS | December 2021 | January 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17554314 | NOVEL CRISPR ENZYMES AND SYSTEMS | December 2021 | June 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17555336 | INSTRUMENTS, MODULES, AND METHODS FOR IMPROVED DETECTION OF EDITED SEQUENCES IN LIVE CELLS | December 2021 | December 2022 | Allow | 12 | 1 | 0 | Yes | No |
| 17554333 | NOVEL CRISPR ENZYMES AND SYSTEMS | December 2021 | February 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17546625 | METHODS FOR SPATIAL ANALYSIS USING TARGETED RNA DEPLETION | December 2021 | July 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17533997 | ENGINEERED PROTEINS | November 2021 | September 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17522425 | METHODS AND SYSTEMS FOR DETERMINING A PREGNANCY-RELATED STATE OF A SUBJECT | November 2021 | April 2022 | Allow | 5 | 1 | 1 | Yes | No |
| 17518556 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST | November 2021 | March 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17518481 | NOVEL MAD NUCLEASES | November 2021 | March 2026 | Abandon | 52 | 0 | 1 | No | No |
| 17453238 | Univariant Extrinsic Initiator Control System For Microbes And An In Vitro Assembly Of Large Recombinant DNA Molecules From Multiple Components | November 2021 | December 2025 | Allow | 50 | 1 | 0 | Yes | No |
| 17505578 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | October 2021 | May 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17450998 | COMPOSITIONS AND METHODS FOR IMPROVING HEALTH THROUGH MODULATING CALHM2 | October 2021 | November 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17475392 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST | September 2021 | February 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17463956 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST | September 2021 | February 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17459053 | DEVICES AND METHODS FOR PRODUCING NUCLEIC ACIDS AND PROTEINS | August 2021 | November 2025 | Allow | 50 | 1 | 0 | Yes | No |
| 17398951 | METHODS AND COMPOSITIONS FOR ALTERING FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND/OR DOMAINS | August 2021 | January 2026 | Abandon | 53 | 1 | 0 | No | No |
| 17310205 | METHOD OF PRODUCING TRANSDUCTION PARTICLES | July 2021 | September 2025 | Allow | 50 | 2 | 1 | No | No |
| 17378394 | HIGH-THROUGHPUT DEEP SEQUENCING OF NUCLEIC ACIDS ACROSS TUMORS AND CLONES WITHIN TUMORS | July 2021 | October 2025 | Allow | 51 | 4 | 0 | No | No |
| 17305649 | MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS, AND TISSUES | July 2021 | August 2022 | Allow | 13 | 3 | 0 | Yes | No |
| 17368698 | METHODS OF PRODUCING TWO CHAIN PROTEINS IN BACTERIA | July 2021 | January 2026 | Abandon | 55 | 1 | 0 | No | No |
| 17355081 | INCREASED NUCLEIC-ACID GUIDED CELL EDITING IN YEAST | June 2021 | January 2026 | Abandon | 55 | 1 | 0 | No | No |
| 17353282 | CURING FOR RECURSIVE NUCLEIC ACID-GUIDED CELL EDITING | June 2021 | December 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17346020 | DNA-BINDING PROTEINS AND USES THEREOF | June 2021 | December 2025 | Abandon | 54 | 1 | 0 | No | No |
| 17339617 | INTEGRATION OF NUCLEIC ACID CONSTRUCTS INTO EUKARYOTIC CELLS WITH A TRANSPOSASE FROM ORYZIAS | June 2021 | February 2022 | Allow | 9 | 1 | 1 | No | No |
| 17334933 | PRODUCTION OF INSULIN PRODUCING CELLS | May 2021 | February 2026 | Abandon | 56 | 1 | 0 | No | No |
| 17332503 | ITERATIVE GENOME EDITING IN MICROBES | May 2021 | January 2022 | Allow | 7 | 1 | 0 | No | No |
| 17330826 | IMMUNOGENIC COMPOSITIONS AND USES THEREOF | May 2021 | November 2025 | Abandon | 53 | 1 | 0 | No | No |
| 17329137 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION | May 2021 | May 2023 | Abandon | 24 | 1 | 1 | No | No |
| 17319022 | SIMULTANEOUS MULTIPLEX GENOME EDITING IN YEAST | May 2021 | September 2021 | Allow | 4 | 1 | 0 | No | No |
| 17313777 | DNA IMPURITIES IN A COMPOSITION COMPRISING A PARVOVIRAL VIRION | May 2021 | March 2026 | Allow | 58 | 4 | 0 | No | No |
| 17290968 | PROGRAMMABLE NUCLEASES AND BASE EDITORS FOR MODIFYING NUCLEIC ACID DUPLEXES | May 2021 | December 2025 | Abandon | 56 | 0 | 1 | No | No |
| 17290787 | MODIFIED CLOSED-ENDED DNA (CEDNA) COMPRISING SYMMETRICAL MODIFIED INVERTED TERMINAL REPEATS | May 2021 | October 2025 | Abandon | 53 | 0 | 1 | No | No |
| 17245928 | MANIPULATION OF GENES INVOLVED IN SIGNAL TRANSDUCTION TO CONTROL FUNGAL MORPHOLOGY DURING FERMENTATION AND PRODUCTION | April 2021 | December 2021 | Allow | 7 | 1 | 0 | Yes | No |
| 17246460 | NOVEL CRISPR ENZYMES AND SYSTEMS | April 2021 | February 2026 | Allow | 58 | 10 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEITH, NANCY J.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEITH, NANCY J works in Art Unit 1636 and has examined 803 patent applications in our dataset. With an allowance rate of 71.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 33 months.
Examiner LEITH, NANCY J's allowance rate of 71.2% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LEITH, NANCY J receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEITH, NANCY J is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +49.8% benefit to allowance rate for applications examined by LEITH, NANCY J. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.8% of applications are subsequently allowed. This success rate is in the 30% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 48.0% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 84.6% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 68.4% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.9% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.